Trending Now

Key Takeaways from LFJ’s  Virtual Town Hall: PACCAR Revisited

By John Freund |

On Thursday August 15th, LFJ hosted a Virtual Town Hall titled ‘PACCAR Revisited.’ The live event revisited the PACCAR decision one year later and explored what the future holds for legal funding in the UK and beyond.

Panelists included Ben Knowles (BK), Chair International Arbitration at Clyde & Co LLP, Robert Marven (RM), Barrister at 4 New Square, Nicholas Marler (NM), Head of Technical Underwriting at Litica Ltd, and Neil Purslow (NP), Founder and Chief Investment Officer, Therium Capital Management Limited. The panel discussion was moderated by Tets Ishikawa, Managing Director of LionFish Litigation Finance Limited.

Below are some key takeaways from the event:

We don’t hear much from insurers in regard to the PACCAR issue. Nicholas, from an insurer’s perspective, what are your thoughts?

NM: The ATE insurers’ odyssey through the world of PACCAR is in some ways quite different from that of a litigation funder. At first bluff, you might think that PACCAR doesn’t have anything to do with insurers because it has to do with litigation funding agreements, and you’d never catch an insurer signing an LFA, so what’s the problem?

If you scratch a little deeper though, the reality is quite different. If you as an insurer, insure a funder, and the funder gives an adverse costs indemnity to the claimant, then all of a sudden, the insurer’s contractual fortunes are tied to the funders. If the LFA is unenforceable, then not only can the insurer not collect its contingent premium if there’s a success, but the coverage provided to the funder has vanished–this is because the LFA is unenforceable.

We actually had this exact experience play out. An opportunistic claimant sought to cut the funder out, because it felt emboldened to do so as a result of the PACCAR decision. When they were informed that doing so would void their insurance, which was to their benefit, they magically found the goodwill necessary to resolve things with their funder and an amicable solution was quickly found.

You’ve touched on enforceability. Given how central that is to the heart of the PACCAR issue, Robert, can you share some insights and perspectives on this corse issue?

RM: There are essentially two views on the concept of enforceability. One is that it essentially says there isn’t anything wrong with the contract, just that it can’t be enforced. There is another view which says that the contract is unenforceable, that it is an illegal contract. I don’t agree with that. It seems this is one of the paradoxes of PACCAR, it seems to have rendered unenforceable funding agreements that were perfectly legal under common law.

A lack of enforceability is important to understand as a two-way street. It means the funder cannot enforce, and it also means the claimant cannot enforce. And this is the key to understanding why things have been put right in cases that are still ongoing. A claimant who says to a funder ‘I don’t have to pay you anymore,’ well, a funder could say to the same token, ‘I don’t have to fund your case anymore.’ And we have seen cases that have been over or very nearly over, where the claimants think they don’t need the funder anymore and saying ‘thank you very much, I needed the funding but I don’t have to pay you.’ Or ‘I did pay you, but I want the money back.’

This is where it’s important to remember that enforceability is a two-way street. If all sides want to continue to carry on, then everyone has an incentive in fixing the problem. It’s only where those interests converge that seem to have led to a significant litigation dispute.

Ben, from your perspective, how do you think this affects the UKs standing as a legal jurisdiction?

BK: PACCAR created a mess, and it was an expensive mess, irrespective of where we’re going to end up. There’s been a lot of lawyer’s time figuring out what PACCAR means and where we’re going to go. The PACCAR fix, as I call it, would have cleared things up to some extend. But the absence of that means some of this uncertainty will continue. And uncertainty means additional costs.

We have these various appeals on the funding agreements out there at the moment. I would expect that in some of these cases, there will be appeals that go to the Court of Appeals, and potentially, all the way up to the Supreme Court. My feeling is, when there’s a case to be funded, lawyers will find a way to get that case funded. Although I’d imagine there will be a risk premium attached to that funding, not least because everybody will be getting their funding agreements checked, double-checked and triple-checked. And you may have lawyers who disagree on what’s permissible, and that leads to additional costs at the start of the case.

This session is about PACCAR, but we’d be remiss not to talk about the CJC, given how the two issues merge. Neil, you’re on the consultation group for the CJC review. Are there any insights you’re able to share?

NP: There’s now a working party reporting up to the CJC. We’re expecting an interim report from that working party to come out in late summer or early autumn, and there will be a consultation, and then the final report in the middle of next year. So we’ve put on quite a tight timeline.

From an industry perspective, this review is welcome, unless you’re opposed to the idea of talking about regulation, which I don’t think the industry is. This is a sensible organizational group that is considering these points in a proper and thoughtful way. I would encourage people to get behind the work that ILFA and ALFA are doing here, and I’d also encourage funders to get involved in the consultation phase as well. It’s very important that the CJC are thinking about these points with a full and proper understanding of how funding actually works, so they can understand the impact.

I think it’s also important that the industry makes sure that the review takes place in a proper context, and by ‘proper context’ I mean that there is an understanding that funding does have benefits. So the review should look at how good responsible funding can be encouraged and those benefits can be maximized, rather than looking at funding as a suspicious thing that needs to be controlled and is just a risk. I think there is a very positive message for funding that needs to be emphasized, and I think the CJC needs to look at it through this positive lens, and I’m confident that they will.

To view the entire digital event, click here.

About the author

John Freund

John Freund

Commercial

View All

Litigation Lending Services Funding Queensland Health Class Action

By Harry Moran |

When it comes to the important role that legal funding can play in providing access to justice, some of the most important cases are those that seek to offer that justice to communities who have been the subject of discrimination based on their identity.

In a post on LinkedIn, Litigation Lending Services (LLS) announced that it is funding a class action filed by JGA Saddler and brought on behalf of Aboriginal and Torres Strait Islander peoples against the State of Queensland. The group action focuses on allegations that these communities were subject to racial discrimination by the state in its failure to provide adequate healthcare across Far North and Northwest Queensland.

The representative proceeding, which has been filed with the Federal Court of Australia, represents those people from these communities who were serviced by the North West Hospital and Health Service (NWHHS) and the Torres and Cape Hospital and Health Service (TCHHS). It alleges that between 1996 and 2024, the state breached the Racial Discrimination Act 1975 by preventing these communities from accessing healthcare services “in a manner consistent with their human rights and fundamental freedoms.”

LLS said that it is “committed to supporting access to justice for communities whose voices are too often overlooked.” In a separate post on LinkedIn, Ella Colantonio, chief investment officer at LLS, said that the class action is “a stark reminder of the role litigation can play in challenging systemic inequality and giving voice to communities that have long gone unheard.”

More information about the Queensland Health Class Action can be found on the claim’s website.

CAT Releases Judgment Approving £200m Settlement in Mastercard Class Action

By Harry Moran |

As LFJ covered in February, a settlement in one of the largest group actions in UK history remains one of the most significant events for legal funding in 2025. With arbitration between the litigation funder and class representation still ongoing, the formal approval of the settlement will stand as a landmark moment  in the Mastercard proceedings, even if the final chapter on the case is yet to be written.

The Competition Appeal Tribunal (CAT) has today released the judgment granting the collective settlement approval order (CSAO) for the £200 million settlement in the Merricks v Mastercard class action. The approval of the settlement signifies the conclusion of proceedings that have dominated headlines both for the size of the claim at stake, and the fallout that followed from a dispute between litigation funder Innsworth and Mr Merricks as the class representative over the size of settlement.

The summary of the judgment released by the CAT detailed the division of the £200 million settlement, with the total amount “split into three pots”. 

Pot 1 represents half of the total settlement at £100 million and is ringfenced for class members, with Merricks enlisting the support of claims administrator Epiq Class Action & Claims Solutions for distribution to class members following a six month notice period. Depending on the volume of class members who come forward with a claim, the individual payout to class members will vary, with £45 per member if there is a 5% uptake. There is also a maximum cap of £70 per member “to prevent excessive individual recovery”.

The Pot 2 total of £45,567,946.28 has been ringfenced for litigation funder Innsworth to account to cover its costs and act as the basis for a minimum return for its investment. 

As the CAT’s judgment awarded Innsworth a 1.5 return on its investment, Pot 3 has a dual purpose. This remaining sum of £54,432,053.72 is set aside to fulfil the remaining profit return to Innsworth, and to supplement Pot 1 should more than 5% of class members submit claims. The judgment also requires any leftover amount in Pot 3 should be paid to “a consumer charity or the Access to Justice Foundation so that more than half of the Settlement Sum is distributed to the Class.” 

Whilst the judgment does not put an end to the arbitration that Innsworth has commenced against Mr Merricks over the settlement, it does approve an indemnity of £10 million that Mastercard has given to Mr Merricks as part of the settlement. The CAT stated this personal indemnity “did not impugn the Tribunal’s view of the settlement.”

The full judgment from the CAT in Walter Hugh Merricks CBE v Mastercard Incorporated and Others can be read here.

SIM IP Provides Funding and Strategic Advisory Services to Gene Pool to Drive Global Intellectual Property Monetization

By Harry Moran |

Sauvegarder Investment Management, Inc ("SIM IP"), a Miami-based firm focused on intellectual property-based financing, investment, and monetization, today announced it has entered into a funding and strategic advisory agreement with Gene Pool Technologies.

Gene Pool Technologies ("Gene Pool") focuses on the development, aggregation, and licensing of advanced extraction and processing technologies, with a particular emphasis on solutions applicable to the cannabis and hemp industries. Gene Pool's intellectual property portfolio broadly covers innovations in plant extraction methods, equipment, and systems that enhance quality, safety, and efficiency for producers and manufacturers.

"We believe that Gene Pool brings a disciplined, technology-focused process to intellectual property licensing that aligns with SIM IP's commitment to efficient and transparent value creation," said Jennifer Burdman, Managing Director at SIM IP. "We look forward to collaborating to provide inventors with stronger protection and improved monetization opportunities, while offering industry participants with streamlined access to critical technologies through clear and equitable licensing terms."

Erich Spangenberg, CEO of SIM IP, commented, "Gene Pool is leveraging two key services provided by SIM IP, which includes capital support through a corporate investment and unparalleled, strategic advisory expertise. Gene Pool strategically chose to leverage our capital for both litigation and the anticipated acquisition of additional intellectual property, as well as our extensive expertise in global intellectual property monetization to support execution and business strategy."

Gene Pool partners with innovators and technology owners to ensure their innovations are protected, compensated, and accessible to operators through operator-friendly, non-exclusive licensing agreements. Gene Pool's licensable portfolio includes  over fifty patent assets, with approximately half owned by Gene Pool and the rest being in-licensed from key market innovators.

"Gene Pool was seeking a strategic partner capable of providing capital and supporting the execution of our intellectual property monetization strategy across multiple jurisdictions, including the U.S. and Europe. We're pleased to have identified SIM IP as a partner and to have formalized our collaboration," said Travis Steffen, CEO of Gene Pool. "We met with numerous litigation funding firms; however, only SIM IP demonstrated strategic advisory service capabilities and meaningful experience in global enforcement strategies."

Over the last few years, Gene Pool secured significant legal victories against companies in the cannabis and hemp industries including defending key patent claims in three inter partes review proceedings before the U.S. Patent and Trademark Office; defeating invalidity, non-infringement, and illegality challenges against these claims in U.S. District Court; and most recently obtaining summary judgment from the same court that the Defendants infringed these claims.

About SIM IP

Sauvegarder Investment Management, Inc. ("SIM IP") is a Miami-based firm focused on intellectual property-based financing, investment and monetization opportunities. SIM IP invests across IP as an asset class and across jurisdictions, primarily focusing on the US, Europe, and Asia. Further information is available at www.simip.io. Follow us on LinkedIn, X (Twitter), and Instagram

About Gene Pool Technologies

At Gene Pool Technologies, we believe in industry solutions that recognize inventors, incentivize ongoing R&D, and enable operating companies with seamless access to technologies that will be critical to the long-term success of the Cannabis industry. Our team brings decades of experience across Cannabis and intellectual property and is deeply committed to the success of the industry and the innovation that will continue to drive quality, safety, and efficiency.

Forward-Looking Statements

Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding SIM IP's strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside SIM IP's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of SIM IP's filings with the SEC, including the Registration Statement and the other documents filed by SIM IP. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.